Feel better product launch visibility and first movers advantage to aid its financials; largely maintain buy call on the stock
Global healthcare company Mylan has inked a settlement pack with Genentech and Roche in relation to patents for cancer drug Herceptin (Trastuzumab).
Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.
The Delhi High Court today told Swiss pharma major Roche that it "cannot hang on to" breast cancer drug Trastuzumab, innovated by it, for the rest of its life after having enjoyed the fruits of its patent.
The revenue and profit growth for the company during the quarter was driven predominantly by the sales of Oseltamivir product or generic Tamiflu in the US market and includes profit sharing from our marketing partner, Natco said in a statement.
Twenty-two companies, including Pfizer, Merck, Novartis, Roche, Sanofi and GlaxoSmithKline, will contribute funds and expertise to the project, which is backed by the World Bank.
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
The Delhi High Court has allowed pharma firms, Biocon Ltd and Mylan Pharmaceuticals Pvt Ltd, to continue with manufacture and marketing of their breast cancer drug under their brand names 'CANMAb' and 'HERTRAZ'.
Avastin is a cancer drug but is often used by doctors to treat vision loss even though it has not been approved by the US Food and Drug Administration for that purpose. Studies have shown that eye injections of Avastin curb vision loss.
"Glenmark reached an agreement with Roche/OSI regarding ongoing patent disputes relating to the anti-cancer medicine - Erlotinib Hydrochloride," says the Mumbai-based pharma company in its filing.
While Indian firms have launched a few such products on the domestic market, where regulatory barriers are relatively low, they are being overtaken by European, American and South Korean firms in the race to supply lucrative Western markets.
These targeted medicines represent a completely new way to treat HER2-positive metastatic breast cancer, with which the company aims to help women in India live as long and as well as possible, he added.
Pfizer sought a patent that covers an important chemical formulation of the active compound in the medicine, but the Indian Patent Office said the company would have to establish that the compound for which it is seeking a patent is therapeutically more effective than the active compound.
The US Food and Drug Administration has banned drug imports from an India manufacturing unit of Emcure Pharmaceuticals Ltd over violations of standard manufacturing practices, the latest in a series of Indian firms to face such action.
Pharma cos aim to make essential drugs available to every segment of the population and simultaneously aid in the growth of companies. But the differential pricing strategy is still in nascent stages as it calls for considerable investments in multiple distribution channels.
The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18's Archana Shukla.
Pfizer, the India unit of US drugmaker Pfizer Inc, will challenge the country's patent office for revoking a patent for its cancer drug Sutent.
Cipla has won patent case against Roche, reports CNBC-TV18. It touched a 52-week high of Rs 387.25. At 11:22 hrs the share was quoting at Rs 385.85, up Rs 5.20, or 1.37%.
Dr Reddy's Laboratories launched Ibandronate Sodium tablets in 150 mg strength in the US market on June 29, following an approval from US Food and Drugs Administration (FDA), the pharma company said on Monday.
It's a drug war, but with a difference and it's been kicked off by Cipla. CNBC TV18's Archana Shukla reports that country's second largest drug firm has slashed prices of three of its key cancer drugs by more than half, making cancer medication costs come down by over 50%.
Dr Reddy's Laboratories has received US Food and Drug Administration's approval for selling ibandronate sodium tablets used to treat osteoporosis, the regulator's website showed on Thursday.
Swiss drugmaker Roche said on Wednesday it would not extend a USD 6.8 billion hostile offer for genetic specialist Illumina as the US group's shareholders blocked its move to appoint new directors.